These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26518947)

  • 1. Efficacy and Safety of Basiliximab Versus Daclizumab in Kidney Transplantation: A Meta-Analysis.
    Sun ZJ; Du X; Su LL; Zhang XD; Wang W
    Transplant Proc; 2015 Oct; 47(8):2439-45. PubMed ID: 26518947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody induction therapy for lung transplant recipients.
    Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
    Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
    Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
    Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 receptor antagonist does not decrease biopsy-proven acute rejection among adult Chinese kidney transplant recipients.
    Lo YC; Ho HC; Wu MJ; Chen CH; Cheng CH; Yu TM; Chuang YW; Huang ST; Yang CK; Shu KH
    Ren Fail; 2012; 34(7):856-61. PubMed ID: 22583338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
    Pascual J; Marcén R; Ortuño J
    Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
    Jirasiritham S; Sumethkul V; Mavichak V; Lertsithichai P; Jirasiritham S
    Transplant Proc; 2004 Sep; 36(7):2110-2. PubMed ID: 15518764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
    Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
    Front Immunol; 2021; 12():749266. PubMed ID: 34621279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies.
    Crins ND; Röver C; Goralczyk AD; Friede T
    Pediatr Transplant; 2014 Dec; 18(8):839-50. PubMed ID: 25283839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.
    Fang J; Hu C; Hong M; Wu Q; You Y; Zhong Z; Li W; Zou P; Hu Y; Xia L
    Biol Blood Marrow Transplant; 2012 May; 18(5):754-62. PubMed ID: 21963619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
    Pham K; Kraft K; Thielke J; Oberholzer J; Sankary H; Testa G; Benedetti E
    Transplant Proc; 2005 Mar; 37(2):899-902. PubMed ID: 15848569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
    Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Spasovski G; Sikole A; Paneva-Masin J
    Transplant Proc; 2001; 33(7-8):3203-4. PubMed ID: 11750374
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
    Aktas S; Colak T; Baskin E; Sevmis S; Ozdemir H; Moray G; Karakayali H; Haberal M
    Transplant Proc; 2011 Mar; 43(2):453-7. PubMed ID: 21440732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
    Nair MP; Nampoory MR; Johny KV; Costandi JN; Abdulhalim M; El-Reshaid W; Al-Muzairai I; Ninan VT; Samhan M; Al-Mousawi M
    Transplant Proc; 2001 Aug; 33(5):2767-9. PubMed ID: 11498153
    [No Abstract]   [Full Text] [Related]  

  • 18. [Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects].
    ter Meulen CG; Hilbrands LB; van Riemsdijk-van Overbeeke IC; Hené RJ; Christiaans MH; Hoitsma AJ
    Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2396-400. PubMed ID: 11145094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M; Ming A; Zhao M
    Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F
    Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.